Fluidigm Announces Third Quarter 2018 Financial Results

South San Francisco, California, UNITED STATES

Total revenue increases 17 percent to $29.0 million

Mass cytometry revenue growth of 50 percent

Instrument revenue growth of 32 percent

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the third quarter ended September 30, 2018.

Third Quarter Highlights

  • Total revenue increased 17 percent to $29.0 million from $24.7 million in the third quarter of 2017, with mass cytometry revenue growth of 50 percent and total instrument revenue growth of 32 percent compared to the year ago period.
  • GAAP net loss was $14.8 million, compared with a GAAP net loss of $15.9 million for the third quarter of 2017.
  • Non-GAAP net loss was $5.2 million, compared with a $8.6 million non-GAAP net loss for the third quarter of 2017.

“We are pleased with the strong operational performance this quarter driven by revenue growth around the world, led by mass cytometry,” said Chris Linthwaite, President and CEO.

“This quarter, we delivered robust global sales in mass cytometry for instruments and consumables with strong global placements of Hyperion Imaging System, leading a new path forward for high-multiplex imaging. Driving future market expansion for our Hyperion Imaging System, a new contract research organization just announced the launch of their Imaging Mass Cytometry services with a pipeline of pharma research projects,” added Linthwaite.

“Our technologies continue to generate pioneering multi-omic insights with the publication of the 10,000 Immunome Project, the launch of two total RNA single cell sequencing applications for C1 and an important clinical study that used mass cytometry to characterize T cells. This progress represents the achievement of key milestones in accelerating our market expansion efforts.  Looking ahead, we are focused on driving growth in 2019 and beyond as we execute on our long-term strategy to provide indispensable tools to power future health care insights.”

A full reconciliation of GAAP to non-GAAP measures can be found in the tables of this news release.

Third Quarter 2018 Results

Revenue by category:

CategoryRevenue by CategoryYear-over-Year Change% of Total Revenue
Instruments$13.9 million32%48%
Consumables$10.4 million3%36%
Service$4.7 million14%16%

Revenue by market:

  • Mass cytometry revenue, comprising instruments, consumables, and service, increased 50 percent to $17.9 million from $11.9 million in the prior year period. Mass cytometry product revenue increased 48 percent to $15.2 million from $10.3 million in the prior year.
  • Genomics revenue, comprising instruments, consumables, and service, decreased 13 percent to $11.1 million from $12.8 million in the prior year period. Genomics product revenue decreased 12 percent to $9.0 million from $10.3 million in the prior year period due to lower sales of high-throughput and single-cell genomics products.

Total revenue by geographic area:

Geographic AreaRevenue by GeographyYear-over-Year Change% of Total Revenue
United States$13.3 million19%46%
Europe$8.8 million14%30%
Asia-Pacific$6.5 million34%23%
Other$0.4 million(59%)1%

Product margin:

GAAP product margin was 52.0 percent in the third quarter of 2018 compared to 44.5 percent in the year ago period and 48.8 percent in the second quarter. Non-GAAP product margin was 66.0 percent in the third quarter of 2018 compared to 62.1 percent in the year ago period and 65.0 percent in the second quarter. The year-over-year and sequential increases in product margins were due to higher plant utilization and favorable product mix, and in the case of GAAP margin, were coupled with fixed amortization over higher revenue.

Cash, cash equivalents, and investments as of September 30, 2018:

Cash, cash equivalents, and investments as of September 30, 2018, were $35.8 million. Cash, cash equivalents, and investments as of June 30, 2018, were $40.4 million.

Operational and Business Progress

Market expansion:

  • Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development:  SironaDx, a specialized contract research organization that provides high-quality clinical research services to pharmaceutical and clinical research clients, announced the introduction of Imaging Mass Cytometry™ services on the Fluidigm Hyperion™ Imaging System to advance biomarker discovery and therapeutic development.

  • Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System: In October, Fluidigm announced the publication of the 10,000 Immunomes Project, a seminal human immune reference standard containing mass cytometry immune cell profiles, by investigators at the University of California, San Francisco, and the Northrop Grumman Information Systems Health IT. Released in Cell Reports, the 10,000 Immunomes Project reference includes standardized measurements of the immune system from 10,344 healthy human subjects varying by age, sex, ethnicity, and state of pregnancy.

New product innovations:

  • Single-Cell Total RNA Sequencing Applications for the C1™ system: In September, Fluidigm launched two new total RNA sequencing applications for the C1, providing researchers with new tools to deeply characterize unique cellular subtypes and functional states.

Strategic agreements:

  • Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry™ Data Analysis: In September, Fluidigm and Visiopharm A/S announced a co-marketing agreement to expand the suite of Hyperion™ Imaging System data analysis tools for translational and clinical research. Visiopharm® Phenomap™ software automates image analysis for Imaging Mass Cytometry, providing automated cell segmentation and phenotyping of cell classes in addition to powerful visualization of cell populations with phenotypic charting and t-SNE clustering.
  • Agreement with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on the Biomark HD system: In September, Fluidigm and GenomOncology announced an expanded Immuno-Oncology Gene Expression Workflow providing a best-in-class solution for immuno-oncology research from RNA extraction to comprehensive data analysis to advance therapeutic development. The GO Immuno-Oncology Workbench is a powerful software tool that enables comprehensive analysis of immuno-oncology cohorts, integrating molecular and phenotypic data together with immuno-oncology-specific annotations to power translational studies.

Fourth Quarter 2018 Guidance  

  • Total revenue of $­­­­­­29 million to $32 million.
  • GAAP operating expenses of $28.5 million to $29.5 million.
  • Non-GAAP operating expenses of $25.5 million to $26.5 million excluding stock-based compensation and depreciation and amortization expenses of approximately $2 million and $1 million, respectively. 
  • Total cash outflow of $3 million to $4 million.

Conference Call Information
Fluidigm will host a conference call today, November 1, 2018, at 2:00 p.m. PT (5:00 p.m. ET) to discuss third quarter 2018 financial results and operational progress. Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 6099918. A live webcast of the conference call will be available online from the Investor Relations page of the company’s website at http://investors.fluidigm.com/events.cfm. The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on November 1, 2018.

After the live webcast, the call will be archived on Fluidigm’s Investor Relations page at http://investors.fluidigm.com/. In addition, a telephone replay of the teleconference will be available 90 minutes after the end of the call. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number: 6099918. The telephone replay will be available until November 8.

Statement Regarding Use of Non-GAAP Financial Information
Fluidigm has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three-month periods ended September 30, 2018, and September 30, 2017, as well as projected for the fourth quarter of 2018. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Our estimates of forward-looking non-GAAP operating expenses exclude estimates for stock-based compensation expense and depreciation and amortization; loss on disposal of property and equipment; future changes relating to developed and acquired technologies; other intangible assets; and income taxes, among other items, certain of which are presented in the tables accompanying our earnings release. The time and amount of certain material items needed to estimate non-GAAP financial measures are inherently unpredictable or outside of our control. Material changes to any of these items could have a significant effect on guidance and future GAAP results. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Fluidigm encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding anticipated applications and benefits of collaborations and new tools, progress in market expansion efforts, and projected revenues, expenses, and cash flows for the fourth quarter of 2018. Forward‑looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to reliance on sales of capital equipment for a significant proportion of revenues in each quarter; potential product performance and quality issues; the possible loss of key employees, customers, or suppliers; intellectual property risks; competition; uncertainties in contractual relationships; Fluidigm research and development, sales, marketing, and distribution plans and capabilities; reduction in research and development spending or changes in budget priorities by customers; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm's business and operating results is contained in the Fluidigm Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission, including the Fluidigm Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Fluidigm, the Fluidigm logo, Biomark, C1, Hyperion, and Imaging Mass Cytometry are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners.


Agnes Lee
Vice President, Investor Relations
Fluidigm Corporation
650 416 7423

(In thousands, except per share amounts)
 Three Months Ended September 30, Nine Months Ended September 30,
 2018 2017 2018 2017
Instruments$  13,890  $  10,518  $  31,831  $  31,183 
Consumables   10,352     10,058     34,665     30,200 
Product revenue   24,242     20,576     66,496     61,383 
Service revenue   4,721     4,133     14,143     12,620 
License revenue   -  $  38     -     190 
Total revenue   28,963     24,747     80,639     74,193 
Costs and expenses:       
Cost of product revenue   11,635     11,414     33,017     33,060 
Cost of service revenue   1,506     1,150     4,784     3,437 
Research and development   7,430     7,683     22,072     23,668 
Selling, general and administrative   20,020     20,102     57,812     63,653 
Total costs and expenses   40,591     40,349     117,685     123,818 
Loss from operations   (11,628)    (15,602)    (37,046)     (49,625)
Interest expense   (4,019)    (1,456)    (9,824)    (4,367)
Other income, net   117     379     465     571 
Loss before income taxes   (15,530)    (16,679)    (46,405)    (53,421)
Income tax benefit   780     735     2,167     3,343 
Net loss$  (14,750) $  (15,944) $  (44,238) $  (50,078)
Net loss per share, basic and diluted$  (0.38) $  (0.46) $  (1.13) $  (1.61)
Shares used in computing net loss per share, basic and diluted 39,235   34,513   39,033   31,051 

(In thousands)
 September 30, 2018 December 31, 2017 (1)
Current assets:   
Cash and cash equivalents$  35,829 $  58,056
Short-term investments   -    5,080
Accounts receivable, net   18,379    15,049
Inventories   15,424    15,088
Prepaid expenses and other current assets   2,228    1,528
Total current assets   71,860    94,801
Property and equipment, net   9,760    12,301
Other non-current assets   6,362    7,541
Developed technology, net   60,200    68,600
Goodwill   104,108    104,108
Total assets$  252,290 $  287,351
Current liabilities:   
Accounts payable$  6,246 $  4,211
Accrued compensation and related benefits   14,526    10,535
Other accrued liabilities   6,582    8,490
Deferred revenue, current portion   11,511    10,238
Total current liabilities   38,865    33,474
Convertible notes, net   169,345    195,238
Deferred tax liability, net   13,790    16,919
Other non-current liabilities   7,878    10,785
Total liabilities   229,878    256,416
Total stockholders' equity   22,412    30,935
Total liabilities and stockholders' equity$  252,290 $  287,351

(1) Derived from audited consolidated financial statements

(In thousands)
 Nine Months Ended September 30,
 2018 2017
Operating activities   
Net loss$  (44,238) $  (50,078)
Depreciation and amortization   4,123     5,578 
Stock-based compensation expense   6,057     7,097 
Amortization of developed technology   8,400     8,400 
Amortization of debt discounts, premiums and issuance costs   5,715     242 
Other non-cash items   40     (535)
Changes in assets and liabilities, net   (4,660)    4,537 
Net cash used in operating activities   (24,563)    (24,759)
Investing activities   
Purchases of investments   (1,451)    (1,450)
Proceeds from sales and maturities of investments   6,541     24,375 
Purchases of property and equipment   (352)    (1,388)
Net cash provided by investing activities   4,738     21,537 
Financing activities   
Payment of debt issuance costs   (2,779)    - 
Proceeds from issuance of common stock through stock plans   562     28,843 
Proceeds from exercise of stock options   25     63 
Payments for taxes related to net share settlement of equity awards   (100)    (90)
Net cash (used in) provided by financing activities   (2,292)    28,816 
Effect of foreign exchange rate fluctuations on cash and cash equivalents   (110)    305 
Net (decrease) increase in cash and cash equivalents   (22,227)    25,899 
Cash and cash equivalents at beginning of period   58,056     35,045 
Cash and cash equivalents at end of period$  35,829  $  60,944 

(In thousands, except per share amounts)
 Three Months Ended September 30,  Nine Months Ended September 30,
 2018 2017 2018 2017
Net loss (GAAP)$  (14,750) $  (15,944) $  (44,238) $  (50,078)
Stock-based compensation expense   2,303     2,322     6,057     7,097 
Amortization of developed technology  (a)   2,800     2,800     8,400     8,400 
Interest expense (b)   4,019     1,456     9,824     4,367 
Depreciation and amortization   1,281     1,658     4,123     5,578 
Benefit from acquisition related income taxes (c)   (898)    (877)    (2,525)    (2,535)
Loss on disposal of property and equipment   -     1     -     1 
Net loss (Non-GAAP)$  (5,245) $  (8,584) $  (18,359) $  (27,170)
Shares used in net loss per share calculation - basic and diluted (GAAP and Non-GAAP)   39,235     34,513     39,033     31,051 
Net loss per share - basic and diluted (GAAP)$  (0.38) $  (0.46) $  (1.13) $  (1.61)
Net loss per share - basic and diluted (Non-GAAP)$  (0.13) $  (0.25) $  (0.47) $  (0.88)
 Three Months Ended September 30,  Nine Months Ended September 30,
 2018 2017 2018 2017
Product margin (GAAP)$  12,607  $  9,162  $  33,479  $  28,323 
Amortization of developed technology  (a)   2,800     2,800     8,400     8,400 
Depreciation and amortization (d)   472     533     1,491     1,627 
Stock-based compensation expense (d)   125     285     550     854 
Product margin (Non-GAAP)$  16,004  $  12,780  $  43,920  $  39,204 
Product margin percentage (GAAP) 52.0%  44.5%  50.3%  46.1%
Product margin percentage (Non-GAAP) 66.0%  62.1%  66.0%  63.9%
 Three Months Ended September 30,  Nine Months Ended September 30,
 2018 2017 2018 2017
Operating expenses (GAAP)$  27,450  $  27,785  $  79,884  $  87,321 
Stock-based compensation expense (e)   (2,177)    (2,037)    (5,506)    (6,243)
Depreciation and amortization (e)   (809)    (1,125)    (2,633)    (3,951)
Loss on disposal of property and equipment (e)   -     (1)    -     (1)
Operating expenses (Non-GAAP)$  24,463  $  24,622  $  71,745  $  77,126 
 Three Months Ended September 30,  Nine Months Ended September 30,
 2018 2017 2018 2017
Loss from operations (GAAP)$  (11,628) $  (15,602) $  (37,046) $  (49,625)
Stock-based compensation expense   2,303     2,322     6,057     7,097 
Amortization of developed technology  (a)   2,800     2,800     8,400     8,400 
Depreciation and amortization (e)   1,281     1,658     4,123     5,578 
Loss on disposal of property and equipment (e)   -     1     -     1 
Loss from operations (Non-GAAP)$  (5,244) $  (8,821) $  (18,466) $  (28,549)

(a) represents amortization of developed technology in connection with the DVS acquisition
(b) represents interest expense on Senior Convertible Notes
(c) represents the tax impact on the purchase of intangible assets in connection with the DVS acquisition
(d) represents expense associated with cost of product revenue
(e) represents expense associated with research and development, selling, general and administrative activities